|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Loblaw DA, Walker- Dilks C, Winquist E and
Hotte SJ; Genitourinary Cancer Disease Site Group of Cancer Care
Ontario's Program in Evidence- Based Care: Systemic therapy in men
with metastatic castration- resistant prostate cancer: A systematic
review. Clin Oncol (R Coll Radiol). 25:406–430. 2013. View Article : Google Scholar
|
|
3
|
Hessels D and Schalken JA: Urinary
biomarkers for prostate cancer: A review. Asian J Androl.
15:333–339. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gong AY, Eischeid AN, Xiao J, Zhao J, Chen
D, Wang ZY, Young CY and Chen XM: miR-17-5p targets the
p300/CBP-associated factor and modulates androgen receptor
transcriptional activity in cultured prostate cancer cells. BMC
Cancer. 12:4922012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hayashita Y, Osada H, Tatematsu Y, Yamada
H, Yanagisawa K, Tomida S, Yatabe Y, Kawahara K, Sekido Y and
Takahashi T: A polycistronic microRNA cluster, miR-17-92, is
overexpressed in human lung cancers and enhances cell
proliferation. Cancer Res. 65:9628–9632. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
He L, Thomson JM, Hemann MT,
Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe
SW, Hannon GJ and Hammond S: A microRNA polycistron as a potential
human oncogene. Nature. 435:828–833. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tagawa H and Seto M: A microRNA cluster as
a target of genomic amplification in malignant lymphoma. Leukemia.
19:2013–2016. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bosch DA: Stereotactic rostral
mesencephalotomy in cancer pain and deafferentation pain. A series
of 40 cases with follow-up results. J Neurosurg. 75:747–751. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang X, Du WW, Li H, Liu F, Khorshidi A,
Rutnam ZJ and Yang BB: Both mature miR-17-5p and passenger strand
miR-17-3p target TIMP3 and induce prostate tumor growth and
invasion. Nucleic Acids Res. 41:9688–9704. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang J, Zhang Z, Chen C, Liu Y, Si Q,
Chuang TH, Li N, Gomez-Cabrero A, Reisfeld RA, Xiang R and Luo Y:
MicroRNA-19a-3p inhibits breast cancer progression and metastasis
by inducing macrophage polarization through downregulated
expression of Fra-1 proto-oncogene. Oncogene. 33:3014–3023. 2014.
View Article : Google Scholar
|
|
11
|
Zheng G, Du L, Yang X, Zhang X, Wang L,
Yang Y, Li J and Wang C: Serum microRNA panel as biomarkers for
early diagnosis of colorectal adenocarcinoma. Br J Cancer.
111:1985–1992. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhi F, Shao N, Wang R, Deng D, Xue L, Wang
Q, Zhang Y, Shi Y, Xia X, Wang S, et al: Identification of 9 serum
microRNAs as potential noninvasive biomarkers of human astrocytoma.
Neuro Oncol. 17:383–391. 2015.
|
|
13
|
Ohori M1, Wheeler TM and Scardino PT: The
New American Joint Committee on Cancer and International Union
Against Cancer TNM classification of prostate cancer.
Clinicopathologic correlations. Cancer. 74:104–114. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
15
|
Bali KK and Kuner R: Noncoding RNAs: Key
molecules in understanding and treating pain. Trends Mol Med.
20:437–448. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Schröder FH, Hugosson J, Roobol MJ,
Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H,
Zappa M, et al: Screening and prostate-cancer mortality in a
randomized European study. N Engl J Med. 360:1320–1328. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sylvestre Y, De Guire V, Querido E,
Mukhopadhyay UK, Bourdeau V, Major F, Ferbeyre G and Chartrand P:
An E2F/miR-20a autoregulatory feedback loop. J Biol Chem.
282:2135–2143. 2007. View Article : Google Scholar
|
|
18
|
Pesta M, Klecka J, Kulda V, Topolcan O,
Hora M, Eret V, Ludvikova M, Babjuk M, Novak K, Stolz J and Holubec
L: Importance of miR-20a expression in prostate cancer tissue.
Anticancer Res. 30:3579–3583. 2010.PubMed/NCBI
|
|
19
|
Fuse M, Nohata N, Kojima S, Sakamoto S,
Chiyomaru T, Kawakami K, Enokida H, Nakagawa M, Naya Y, Ichikawa T
and Seki N: Restoration of miR-145 expression suppresses cell
proliferation, migration and invasion in prostate cancer by
targeting FSCN1. Int J Oncol. 38:1093–1101. 2011.PubMed/NCBI
|
|
20
|
Ribas J, Ni X, Haffner M, Wentzel EA,
Salmasi AH, Chowdhury WH, Kudrolli TA, Yegnasubramanian S, Luo J,
Rodriguez R, et al: miR-21: An androgen receptor-regulated microRNA
that promotes hormone-dependent and hormone-independent prostate
cancer growth. Cancer Res. 69:7165–7169. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sun T, Wang Q, Balk S, Brown M, Lee GS and
Kantoff P: The role of microRNA-221 and microRNA-222 in
androgen-independent prostate cancer cell lines. Cancer Res.
69:3356–3363. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Leung CM, Chen TW, Li SC, Ho MR, Hu LY,
Liu WS, Wu TT, Hsu PC, Chang HT and Tsai KW: MicroRNA expression
profiles in human breast cancer cells after multifraction and
single-dose radiation treatment. Oncol Rep. 31:2147–2156.
2014.PubMed/NCBI
|
|
23
|
Xu LL, Shi Y, Petrovics G, Sun C, Makarem
M, Zhang W, Sesterhenn IA, McLeod DG, Sun L, Moul JW and Srivastava
S: PMEPA1, an androgen-regulated NEDD4-binding protein, exhibits
cell growth inhibitory function and decreased expression during
prostate cancer progression. Cancer Res. 63:4299–4304.
2003.PubMed/NCBI
|
|
24
|
Ishkanian AS, Mallof CA, Ho J, Meng A,
Albert M, Syed A, van der Kwast T, Milosevic M, Yoshimoto M, Squire
JA, et al: High-resolution array CGH identifies novel regions of
genomic alteration in intermediate-risk prostate cancer. Prostate.
69:1091–1100. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rae FK, Hooper JD, Nicol DL and Clements
JA: Characterization of a novel gene, STAG1/PMEPA1, upregulated in
renal cell carcinoma and other solid tumors. Mol Carcinog. 2:44–53.
2001. View
Article : Google Scholar
|
|
26
|
Tanner MM, Tirkkonen M, Kallioniemi A,
Collins C, Stokke T, Karhu R, Kowbel D, Shadravan F, Hintz M, Kuo
WL, et al: Increased copy number at 20q13 in breast cancer:
Defining the critical region and exclusion of candidate genes.
Cancer Res. 54:4257–4260. 1994.PubMed/NCBI
|
|
27
|
Reichling T, Goss KH, Carson DJ, Holdcraft
RW, Ley-Ebert C, Witte D, Aronow BJ and Groden J: Transcriptional
profiles of intestinal tumors in Apc(Min) mice are unique from
those of embryonic intestine and identify novel gene targets
dysregulated in human colorectal tumors. Cancer Res. 65:166–176.
2005.PubMed/NCBI
|
|
28
|
Liu R, Zhou Z, Huang J and Chen C: PMEPA1
promotes androgen receptor-negative prostate cell proliferation
through suppressing the Smad3/4-c-Myc-p21 Cip1 signaling pathway. J
Pathol. 223:683–694. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hirokawa YS, Takagi A, Uchida K, Kozuka Y,
Yoneda M, Watanabe M and Shiraishi T: High level expression of
STAG1/PMEPA1 in an androgen-independent prostate cancer PC3
subclone. Cell Mol Biol Lett. 12:370–377. 2007. View Article : Google Scholar : PubMed/NCBI
|
